Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2013

Galena Buys Orexo’s Pain Drug for $10M+

  • Orexo sold Abstral® (fentanyl) sublingual tablets to Galena Biopharma. Under the agreement, Galena will pay Orexo $10 million up front and an additional $5 million within the first 12 months after signing, plus low double-digit royalties and milestone payments based on prespecified sales levels.

    Abstral is a sublingual rapid acting formulation of fentanyl, an opioid, and is indicated for the management of breakthrough pain. It was approved by the FDA in 2011. In June 2012, Orexo acquired all U.S. rights to Abstral from ProStrakan Group as a part of a reconfiguration of the worldwide rights to Abstral. With completion of the current transaction, Orexo has secured net cash payments of over SEK 700 million ($110 million) and in addition milestones and royalty payments.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »